Pharma BD Deal Intelligence
Bristol-Myers Squibb Company / Eisai Co., Ltd.
2021 · Co-Development · $3.1B · Complete
Announcement Sentiment
44
Skeptical
Outcome Score
45
Mixed — partial payoff, real shortfalls.
BMS and Eisai entered a global co-development collaboration for MORAb-202, a folate receptor alpha-targeting ADC for advanced solid tumors.
Key facts
- Announced Jun 18, 2021
- Deal value $3.1B
- Deal type Co-Development
- Therapeutic area Oncology
- Indications Advanced solid tumors
- Key assets MORAb-202
- Mechanism Folate receptor alpha-targeting antibody-drug conjugate
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals